Diabetes Research and Clinical Practice
Volume 66 , Pages S27-S32 , December 2004

Prevention of type 1 diabetes: from the view point of β cell damage

  • Eiji Kawasaki

      Affiliations

    • Department of Metabolism/Diabetes and Clinical Nutrition, Nagasaki University Hospital of Medicine and Dentistry, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 95 849 7550; fax: +81 95 849 7552.
    • ,
  • Norio Abiru

      Affiliations

    • The First Department of Internal Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
    • ,
  • Katsumi Eguchi

      Affiliations

    • The First Department of Internal Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

Received 30 August 2003 ,Accepted 27 September 2003.

References 

  1. E. Kawasaki, R.G. Gill, G.S. Eisenbarth, Type 1 diabetes, in: G.S. Eisenbarth (Ed.), Endocrine and Organ Specific Autoimmunity, R.G. Landes Co., Austin, TX, 1999, pp. 149–182.
  2. Guz Y , Nasir I , Teitelman G . Regeneration of pancreatic β cells from intra-islet precursor cells in an experimental model of diabetes . Endocrinology . 2001;142:4956–4968
  3. Garcia-Ocana A , Vasavada RC , Cebrian A , Reddy V , Takane KK , Lopez-Talavera JC , et al.   Transgenic overexpression of hepatocyte growth factor in the β cell markedly improves islet function and islet transplant outcomes in mice . Diabetes . 2001;50:2752–2762
  4. Jansen A , Homo-Delarche F , Hooijkaas H , Leenen PJ , Dardenne M , Drexhage HA . Immunohistochemical characterization of monocytes-macrophages and dendritic cells involved in the initiation of the insulitis and β cell destruction in NOD mice . Diabetes . 1994;43:667–675
  5. Suarez-Pinzon WL , Rabinovitch A . Approaches to type 1 diabetes prevention by intervention in cytokine immunoregulatory circuits . Int. J. Exp. Diab. Res . 2001;2:3–17
  6. Mosmann TR , Coffman RL . TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties . Annu. Rev. Immunol . 1989;7:145–173
  7. Jacob CO , Also S , Michie S , McDevitt HO , Acha-Orbea H . Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin 1 . Proc. Natl. Acad. Sci. U.S.A . 1990;87:968–972
  8. Nitta Y , Tashiro F , Tokui M , Shimada A , Takei I , Tabayashi K , et al.   Systemic delivery of interleukin 10 by intramuscular injection of expression plasmid DNA prevents autoimmune diabetes in nonobese diabetic mice . Hum. Gene. Ther . 1998;9:1701–1707
  9. Sobel DO , Ahvazi B . Alpha-interferon inhibits the development of diabetes in NOD mice . Diabetes . 1998;47:1867–1872
  10. Zaccone P , Phillips J , Conget I , Gomis R , Haskins K , Minty A , et al.   Interleukin-13 prevents autoimmune diabetes in NOD mice . Diabetes . 1999;48:1522–1528
  11. Tominaga Y , Nagata M , Yasuda H , Okamoto N , Arisawa K , Moriyama H , et al.   Administration of IL-4 prevents autoimmune diabetes but enhances pancreatic insulitis in NOD mice . Clin. Immunol. Immunopathol . 1998;86:209–218
  12. Piccirillo CA , Chang Y , Prud’homme GJ . TGF-β1 somatic gene therapy prevents autoimmune disease in nonobese diabetic mice . J. Immunol . 1998;161:3950–3956
  13. Jacob CO , Aiso S , Schreiber RD , McDevitt HO . Monoclonal anti-tumor necrosis factor antibody renders non-obese diabetic mice hypersensitive to irradiation and enhances insulitis development . Int. Immunol . 1992;4:611–614
  14. Debray-Sachs M , Carnaud C , Boitard C , Cohen H , Gresser I , Bedossa P , et al.   Prevention of diabetes in NOD mice treated with antibody to murine IFN γ . J. Autoimmun . 1991;4:237–248
  15. Fujihira K , Nagata M , Moriyama H , Yasuda H , Arisawa K , Nakayama M , et al.   Suppression and acceleration of autoimmune diabetes by neutralization of endogenous interleukin-12 in NOD mice . Diabetes . 2000;49:1998–2006
  16. Khachatryan A , Guerder S , Palluault F , Cote G , Solimena M , Valentijn K , et al.   Targeted expression of the neuropeptide calcitonin gene-related peptide to β cells prevents diabetes in NOD mice . J. Immunol . 1997;158:1409–1416
  17. Moritani M , Yoshimoto K , Wong SF , Tanaka C , Yamaoka T , Sano T , et al.   Abrogation of autoimmune diabetes in nonobese diabetic mice and protection against effector lymphocytes by transgenic paracrine TGF-β1 . J. Clin. Invest . 1998;102:499–506
  18. Gallichan WS , Balasa B , Davies JD , Sarvetnick N . Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse . J. Immunol . 1999;163:1696–1703
  19. Kawamoto S , Nitta Y , Tashiro F , Nakano A , Yamato E , Tahara H , et al.   Suppression of T(h)1 cell activation and prevention of autoimmune diabetes in NOD mice by local expression of viral IL-10 . Int. Immunol . 2001;13:685–694
  20. von Herrath MG , Efrat S , Oldstone MB , Horwitz MS . Expression of adenoviral E3 transgenes in β cells prevents autoimmune diabetes . Proc. Natl. Acad. Sci. U.S.A . 1997;94:9808–9813
  21. Loweth AC , Williams GT , James RF , Scarpello JH , Morgan NG . Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1β and Fas ligation . Diabetes . 1998;47:727–732
  22. Stassi G , Todaro M , Richiusa P , Giordano M , Mattina A , Sbriglia MS , et al.   Expression of apoptosis-inducing CD95 (Fas/Apo-1) on human β cells sorted by flow-cytometry and cultured in vitro . Transplant. Proc . 1995;27:3271–3275
  23. Chervonsky AV , Wang Y , Wong FS , Visintin I , Flavell RA , Janeway CA , et al.   The role of Fas in autoimmune diabetes . Cell . 1997;89:17–24
  24. Itoh N , Imagawa A , Hanafusa T , Waguri M , Yamamoto K , Iwahashi H , et al.   Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice . J. Exp. Med . 1997;186:613–618
  25. Moriwaki M , Itoh N , Miyagawa J , Yamamoto K , Imagawa A , Yamagata K , et al.   Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset Type I diabetes mellitus . Diabetologia . 1999;42:1332–1340
  26. Cottet S , Dupraz P , Hamburger F , Dolci W , Jaquet M , Thorens B . cFLIP protein prevents tumor necrosis factor-α-mediated induction of caspase-8-dependent apoptosis in insulin-secreting βTc-Tet cells . Diabetes . 2002;51:1805–1814
  27. Liu Y , Rabinovitch A , Suarez-Pinzon W , Muhkerjee B , Brownlee M , Edelstein D , et al.   Expression of the bcl-2 gene from a defective HSV-1 amplicon vector protects pancreatic β cells from apoptosis . Hum. Gene. Ther . 1996;7:1719–1726
  28. Rabinovitch A , Suarez-Pinzon W , Strynadka K , Ju Q , Edelstein D , Brownlee M , et al.   Transfection of human pancreatic islets with an anti-apoptotic gene (bcl-2) protects β cells from cytokine-induced destruction . Diabetes . 1999;48:1223–1229
  29. Grankvist K , Marklund SL , Taljedal IB . CuZn-superoxide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse . Biochem. J . 1981;199:393–398
  30. Lenzen S , Drinkgern J , Tiedge M . Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues . Free Radic. Biol. Med . 1996;20:463–466
  31. Cetkovic-Cvrlje M , Eizirik DL . TNF-α and IFN-γ potentiate the deleterious effects of IL-1β on mouse pancreatic islets mainly via generation of nitric oxide . Cytokine . 1994;6:399–406
  32. Corbett JA , McDaniel ML . Does nitric oxide mediate autoimmune destruction of Beta cells? Possible therapuetic interventions in IDDM . Diabetes . 1992;41:897–903
  33. Karlsen AE , Andersen HU , Vissing H , Larsen PM , Fey SJ , Cuartero BG , et al.   Cloning and expression of cytokine-inducible nitric oxide synthase cDNA from rat islets of Langerhans . Diabetes . 1995;44:753–758
  34. Andersson AK , Flodstrom M , Sandler S . Cytokine-induced inhibition of insulin release from mouse pancreatic β cells deficient in inducible nitric oxide synthase . Biochem. Biophys. Res. Commun . 2001;281:396–403
  35. Flodstrom M , Tyrberg B , Eizirik DL , Sandler S . Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes . Diabetes . 1999;48:706–713
  36. Kubisch HM , Wang J , Luche R , Carlson E , Bray TM , Epstein CJ , et al.   Transgenic copper/zinc superoxide dismutase modulates susceptibility to type I diabetes . Proc. Natl. Acad. Sci. U.S.A . 1994;91:9956–9959
  37. Hohmeier HE , Thigpen A , Tran VV , Davis R , Newgard CB . Stable expression of manganese superoxide dismutase (MnSOD) in insulinoma cells prevents IL-1β- induced cytotoxicity and reduces nitric oxide production . J. Clin. Invest . 1998;101:1811–1820
  38. Lortz S , Tiedge M , Nachtwey T , Karlsen AE , Nerup J , Lenzen S . Protection of insulin-producing RINm5F cells against cytokine-mediated toxicity through overexpression of antioxidant enzymes . Diabetes . 2000;49:1123–1130
  39. Hotta M , Tashiro F , Ikegami H , Niwa H , Ogihara T , Yodoi J , et al.   Pancreatic β cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes . J. Exp. Med . 1998;188:1445–1451
  40. Piganelli JD , Flores SC , Cruz C , Koepp J , Batinic-Haberle I , Crapo J , et al.   A metalloporphyrin-based superoxide dismutase mimic inhibits adoptive transfer of autoimmune diabetes by a diabetogenic T cell clone . Diabetes . 2002;51:347–355
  41. Petley A , Macklin B , Renwick AG , Wilkin TJ . The pharmacokinetics of nicotinamide in humans and rodents . Diabetes . 1995;44:152–155
  42. Pozzilli P , Browne PD , Kolb H . Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists . Diab. Care . 1996;19:1357–1363
  43. Lampeter EF , Klinghammer A , Scherbaum WA , Heinze E , Haastert B , Giani G , et al.   DENIS Group, The Deutsche Nicotinamide Intervention Study: an attempt to prevent type 1 diabetes . Diabetes . 1998;47:980–984
  44. The European Nicotinamide Diabetes Intervention Trial (ENDIT) Group, E.A. Gale, Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT), Diabetologia 46 (2003) 339–346.

PII: S0168-8227(04)00156-1

doi: 10.1016/j.diabres.2003.09.015

Diabetes Research and Clinical Practice
Volume 66 , Pages S27-S32 , December 2004

Article Tools

* Image Usage & Resolution